TransRe

Adimab is a Lebanon, New Hampshire-based biotechnology company that makes strategic direct investments in antibody therapeutics. It is most relevant for biotechnology, life sciences and pharmaceutical startups where antibody discovery, engineering or therapeutic development creates strategic alignment, with later-stage venture activity in the United States.